Butterfly Network announced a product co-development deal with surgical robotics startup Mendaera, in which the startup will build custom robotics around Butterfly’s ultrasound-on-a-chip technology to create a new system designed for better surgical precision and consistency. Both partners expect to complete the product’s FDA submission by 2025.
With its new handheld ultrasound device, Exo is seeking to take point-of-care ultrasound beyond just the emergency medicine field — into areas like urgent care, primary care and the home. Kurt Hammond, Exo's chief commercial officer, said that the device sets itself apart from other handheld ultrasound devices, such as those sold by GE, Philips and Butterfly Network, because its AI does a better job of making the ultrasound process quick and easy for providers.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Sonio recently gained $14 million in Series A funding. The Paris-based startup's AI platform automates ultrasound reporting so that healthcare providers can conduct ultrasound exams with greater accuracy, speed and efficiency.
Butterfly Network recently launched an AI tool that can provide medical practitioners with an accurate B-line count from just a six-second lung ultrasound clip. By automatically counting B-lines in a lung image, the tool helps doctors quickly identify and assess a patient's lung issues at the point of care.
GE HealthCare recently announced plans to acquire Caption Health, a company that sells AI software designed to guide cardiac imaging. The company's guidance technology aims to make ultrasound exams easier and faster, as well as allow a broader set of healthcare professionals to conduct basic echocardiography exams.
The company would become part of GE’s ultrasound business, expanding its capabilities to include surgical visualization. GE plans to spin out its healthcare division into a publicly traded company in 2023.
Share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health, healthcare navigation, and more.
The Toronto-based startup is applying AI to ultrasound signals. It differentiates healthy tissue from diseased tissue by measuring its acoustic properties.
Exo Imaging recently raised $35 million in a Series B round to transform the portable ultrasound market in which healthcare unicorn Butterfly Network has a head start.
The portable ultrasound company raised a $250 million Series D financing round led by financial services Fidelity at a $1.25 billion valuation.
Butterfly Network previewed its Tele-Guidance technology at the American Institute of Ultrasound in Medicine (AIUM) Convention in New York City.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Dr. Jonathan Rothberg, founder and chairman of Butterfly Network, predicted the device's impact would be not unlike the milestone development of camera phones.
The ExAblate device's label, an ultrasound technology designed to treat uterine fibroids, has been adapted in order for it to be available to women who want to keep their uterus intact while still having the option to get pregnant.
Michigan startup Delphinus Medical Technologies just raised $39.5 million - the largest medtech fundraise in the Midwest - for its whole breast ultrasound device. It's chasing FDA approval after a study next year of 10,000 women with dense breast tissue.
Among the 14 finalists at TechCrunch’s Disrupt London, three are focused on international challenges in healthcare. Along with the other startups, they are competing for $50,000 and the winner of the European Disrupt Cup. They include the Disease Diagnostic Group, which has offices in Cambridge and Cleveland and which is showcasing its Rapid Assessment of […]
Why wait months to determine whether a tumor is responding to cancer treatment if it’s possible to know sooner? That’s the question being posed by a pair of inventors in Toronto who are crowdfunding clinical studies of a new device to monitor the effectiveness of chemotherapy on breast tumors. Called WaveCheck, the noninvasive device combines […]